ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Alternatives Channel
      • Artificial Intelligence
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Education
      • ETF Investing
      • ETF Strategist
      • Faith-Based Investing
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Invest Beyond Cash
      • Leveraged & Inverse
      • Modern Alpha
      • Portfolio Strategies
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Gold/Silver/Critical Materials
        • Crypytocurrency
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
    • Market Outlook
    • Crypto ETF Hub
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Database Categories
    • Indexes
    • Scenario Analysis
    • Watchlists
    • Head-To-Head ETF Comparison Tool
    • Mutual Fund To ETF Converter
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • Gaining Perspective Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
News
Share

A Targeted ETF to Capture M&A, Consolidation in the Biotech Space

Max ChenApr 10, 2019
2019-04-10

The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has typically tapped into these smaller innovators to fill out their own businesses. With increased merger and acquisition activity in the biotech sector, ETF investors may look to targeted plays to capture the up-and-coming companies.

“We’ve had a lot of activity in the M&A side – mergers and acquisitions, huge deals, which really have driven valuations across the whole space,” Andy Hicks, SVP, Director of Portfolio Management & Research, ALPS, said at Inside ETFs.

As a way to gain exposure to these smaller treatment developers, ETF investors can look to something like the ALPS Medical Breakthroughs ETF (SBIO B-), which focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials.

Biotech ETFs that focus on smaller companies have been enjoying a nice boost this year as larger companies begin to sift through smaller researchers to build up their portfolios.

Many big pharmaceutical and biotechnology companies are no longer relying on blockbuster drug sales as many of their intellectual property rights expire. Instead, many are now relying on targeted or specialized therapies or treatment methods, which has increased the demand for mergers and acquisitions for smaller developers and research companies.

Consequently, investors may turn to targeted plays like the SBIO, which invests in stocks of mid-cap and small-cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.

The component holdings have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. In a Phase II trial, the drug is administered to a group of 100-300 people to see if it is effective and to evaluate its safety. In a Phase III trial, the drug is given to a larger group, between 500-3,000 people, to confirm its effectiveness, monitor side effects, compare it to commonly used treatments and collect information that will allow the drug or treatment to be used safely.

Watch the full interview between ETF Trends CEO Tom Lydon and Andy Hicks


Content continues below advertisement

For more ETF-related commentary from Tom Lydon and other industry experts, visit our video category on our sister site, ETFtrends.com.

» Popular Pages

  • Tickers
  • Articles

Jul 14

World Markets Watchlist: July 14, 2025

Jul 14

J.P. Morgan Says HOLA to Lower-Risk International ETF

Jul 14

Sovereign Adoption Another Bitcoin Catalyst

Jul 14

Despite Economic Uncertainties and Wild Market Swings, U.S. Economic Fundamentals Refuse to Buckle

Jul 14

Top 10 Charts of 2025: Midyear Review

Jul 14

Moderating Dividend Growth Highlights Allure of This ETF

Jul 14

VictoryShares FCF ETF: A Breakdown of Its 3 Core Allocation Themes

Jul 14

1 Big Beautiful Bill Could Energize This ETF Trio

Jul 14

3 Reasons 2025 Tech Investors Need to Consider KWEB

Jul 14

The $10 Billion Club: New Stars in Active Bonds

QQQ

Invesco QQQ Trust Series I

VOO

Vanguard S&P 500 ETF

IBIT

iShares Bitcoin Trust ETF

SPY

SPDR S&P 500 ETF Trust

SCHD

Schwab US Dividend Equity ETF...

IVV

iShares Core S&P 500 ETF

SMH

VanEck Semiconductor ETF

FIAT

YieldMax Short COIN Option...

AIQ

Global X Artificial...

GLD

SPDR Gold Shares


Content continues below advertisement

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2025 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X